Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial

OBJECTIVES: In the phase II FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses (FORWARD) study, sprifermin demonstrated cartilage modification in the total femorotibial joint and in both femorotibial compartments by MRI in patients with knee osteoarthritis. Here, we evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckstein, Felix, Kraines, Jeffrey L, Aydemir, Aida, Wirth, Wolfgang, Maschek, Susanne, Hochberg, Marc C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Osteoarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147175/
https://www.ncbi.nlm.nih.gov/pubmed/32098758
http://dx.doi.org/10.1136/annrheumdis-2019-216453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147175/
https://www.ncbi.nlm.nih.gov/pubmed/32098758
http://dx.doi.org/10.1136/annrheumdis-2019-216453

Ejemplares similares